Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

ш	direct to respond to a conection of information dniess it displays a valid OMB control number.					
	Application Number	10/669,059				
	Filing Date	SEPTEMBER 23, 2003				
	First Named Inventor	VICTOR SCHOENLE				
	Title	MEDICAL DEVICE COMPONENTS AND PROCESSES				
	Art Unit	1794				
	Examiner Name	WALTER AUGHENBAUGH				
	Attorney Docket Number	1001,2325101				

I hereby revoke all previous powers of attorney given in th	e above-identified application							
I hereby revoke all previous powers of attorney given in the above-identified application.								
hereby appoint:								
Practitioners associated with the Customer Number:	28075							
OR L								
Practitioner(s) named below:								
Name	Registration Number							
	_							
	<u></u>							
	have a second of the second of							
as my/our attomey(s) or agent(s) to prosecute the application identified a Trademark Office connected therewith.	above, and to transact all business in the United States Patent and							
Disease recognize as about the correspondence of disease for the characteristics	identified application to							
Please recognize or change the correspondence address for the above-								
The address associated with the above-mentioned Customer N	łumber:							
The address associated with Customer Number:								
OR								
Individual Name								
Address								
City	State Zip							
Country	Tem 1							
Telephone	Fax							
lam the:								
Applicant/Inventor.								
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 3/CFR 3.73(b) is enclosed. (Form PTO/SB/9)	(6)							
1 SIGNATURE of Applican								
Signature Kourt (Al) No.	Date SEPTEMBER 11, 2008 Telephone 70.3 JQU 247.5							
	11.3. 1.1.2.2.2							
NOTE. Signatures of all the inventors or assignees of record of the entire Interest or their representative(s) are required. Submit multiple forms if more than one								
signature is required, see below*.								
*Total of forms are submitted.								

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gettering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE REGARDING CERTAIN PATENT MATTERS

EFFECTIVE THROUGH: December 31, 2008

I, Lawrence J. Knopf, as Senior Vice President and Deputy General Counsel of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Advanced Stent Technologies, Inc.; AFx, Inc.; AMS Medinvent S.A.; BEI Medical Systems; BEI Medical Systems Operating Company (formerly known as Xylog Corporation), BEI Medical Systems International, Inc.; Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Ireland Limited, Boston Scientific Japan KK; Boston Scientific Limited, Boston Scientific Neuromodulation Corporation; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation; Cardiothoracic Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Corvita Canada, Inc.; Corvita Corporation, Corvita Europe S.A.; CryoVascular Systems, Inc.; Embolic Protection, Inc.; Embro Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidus Medical Technology Corporation; Guidant Corporation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technologies; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Laboratoires Corvita S.A.R.L.; Meadox Medicals, Inc.; NAMIC Eireann Limited; NAMIC International, Inc.; Nilo Holding, S.A.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc., Quanum Corporation; Radio Therapeutics Corporation; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC, Scimed Life Systems, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; TriVascular, Inc.; and Vesica;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera Poissant	7,420 9,634 1,751 8,649 6,783 6,517 3,667	Philip H. Lee Kurt W. Lockwood Jeffrey Z. Mann Steven A. McAuley Todd P. Messal Tyler L. Nasiedlak William J. Shaw Sarah G. Stolpman	Reg. No. 40,704 Reg. No. 51,994 Reg. No. 46,084 Reg. No. 42,883 Reg. No. 40,099 Reg. No. 43,111
Albert K. Kau		Saran G. Stoipman	.keg. No. 57,000

Lawrence J. Knopf, Senior Vice President and Deputy General Counsel

COMMONWEALTH	OF	MASSA	CHUSETT	'S

E Khal

COUNTY OF MIDDLESEX

On this 9n day of January 2008 before me personally appeared Lawrence J. Knopf to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.

Notary Public

Nona E Hurd NOTARY PUBLIC Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner: VICTOR SCHOENLE et al.				
Application No./Patent No.: 10/669,059 Filed/Issue Date: SEPTEMBER 23, 2003				
Entitled: MEDICAL DEVICE COMPONENTS AND PROCESSES				
SCIMED LIFE SYSTEMS, INC. , a CORPORATION (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)				
states that it is: 1 the assignee of the entire right, title, and interest; or				
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is				
in the patent application/patent identified above by virtue of either:				
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:				
From: VICTOR SCHOENLE et al. To: SCIMED LIFE SYSTEMS, INC. The document was recorded in the United States Patent and Trademark Office at Reel 015305 , Frame 0706 , or for which a copy thereof is attached. Respectively.				
From: SCIMED LIFE SYSTEMS, INC. To: BOSTON SCIENTIFIC SCIMED, INC. The document was recorded in the United States Patent and Trademark Office at Reel 018505 , Frame 0868 , or for which a copy thereof is attached.				
3. From:To:				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
Additional documents in the chain of title are listed on a supplemental sheet.				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
Signature Date				
J. SCOT WICKHEM 612.677.9050 Printed or Typed Name Telephone Number				
ATTORNEY FOR APPLICANT(S)				
Title				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.